Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.43 +2.1%	$1.35	$1.01 ▼ $3.45	$405.07M	1.14	1.87 million shs	3.16 million shs
LCTX Lineage Cell Therapeutics	$0.47 +2.4%	$0.50	$0.37 ▼ $1.40	$103.82M	1.21	1.33 million shs	740,770 shs
NWBO Northwest Biotherapeutics	$0.30 +5.4%	$0.25	$0.17 ▼ $0.54	$418.55M	-0.67	4.10 million shs	2.97 million shs
SANA Sana Biotechnology	$1.71 -2.8%	$2.07	$1.26 ▼ $10.50	$384.79M	1.78	3.30 million shs	1.62 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	+0.72%	+12.90%	-7.89%	-26.32%	-25.93%
LCTX Lineage Cell Therapeutics	-6.12%	+15.00%	-6.49%	-26.97%	-59.65%
NWBO Northwest Biotherapeutics	-10.94%	-35.13%	+21.16%	-0.66%	-41.44%
SANA Sana Biotechnology	-0.56%	+10.69%	+2.92%	-48.39%	-79.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	3.204 of 5 stars	3.5	2.0	3.0	3.3	1.3
LCTX Lineage Cell Therapeutics	1.8719 of 5 stars	3.5	0.0	1.3	3.3	0.6
NWBO Northwest Biotherapeutics	0.1094 of 5 stars	0.0	3.0	0.6	0.0	0.0
SANA Sana Biotechnology	1.9232 of 5 stars	3.4	0.0	1.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	3.00	Buy	$4.83	238.00% Upside
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.20	791.72% Upside
NWBO Northwest Biotherapeutics	0.00	N/A	N/A	N/A
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	531.58% Upside

Current Analyst Ratings Breakdown

Latest LCTX, NWBO, ERAS, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/26/2025	ERAS Erasca	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
3/21/2025	ERAS Erasca	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/21/2025	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/18/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/18/2025	SANA Sana Biotechnology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00
3/14/2025	LCTX Lineage Cell Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
3/14/2025	SANA Sana Biotechnology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$7.00
3/11/2025	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/11/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00 ➝ $2.00
3/7/2025	ERAS Erasca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$4.00 ➝ $4.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$2.10 per share	N/A
LCTX Lineage Cell Therapeutics	$8.94M	11.61	N/A	N/A	$0.35 per share	1.35
NWBO Northwest Biotherapeutics	$1.93M	216.87	N/A	N/A	($0.06) per share	-4.97
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$125.04M	-$0.74	N/A	N/A	N/A	N/A	-42.26%	-34.97%	5/14/2025 (Estimated)
LCTX Lineage Cell Therapeutics	-$21.49M	-$0.12	N/A	N/A	N/A	-230.66%	-30.39%	-19.67%	5/8/2025 (Estimated)
NWBO Northwest Biotherapeutics	-$62.60M	-$0.08	N/A	∞	N/A	-4,666.29%	N/A	-261.36%	5/8/2025 (Estimated)
SANA Sana Biotechnology	-$283.26M	-$1.16	N/A	N/A	N/A	N/A	-84.22%	-44.97%	5/6/2025 (Estimated)

Latest LCTX, NWBO, ERAS, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ERAS Erasca	-$0.12	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	LCTX Lineage Cell Therapeutics	-$0.02	N/A	N/A	N/A	$1.72 million	N/A
3/31/2025	Q4 2024	NWBO Northwest Biotherapeutics	N/A	-$0.02	N/A	-$0.02	N/A	$0.23 million
3/20/2025	Q4 2024	ERAS Erasca	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
3/17/2025	Q4 2024	SANA Sana Biotechnology	-$0.25	-$0.23	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	11.00	11.00
LCTX Lineage Cell Therapeutics	N/A	2.48	2.48
NWBO Northwest Biotherapeutics	N/A	0.09	0.09
SANA Sana Biotechnology	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
LCTX Lineage Cell Therapeutics	62.47%
NWBO Northwest Biotherapeutics	0.04%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	21.50%
LCTX Lineage Cell Therapeutics	23.60%
NWBO Northwest Biotherapeutics	8.70%
SANA Sana Biotechnology	31.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.27 million	221.94 million	Optionable
LCTX Lineage Cell Therapeutics	60	220.42 million	168.40 million	Not Optionable
NWBO Northwest Biotherapeutics	20	1.40 billion	1.24 billion	Not Optionable
SANA Sana Biotechnology	380	225.03 million	153.83 million	Optionable

LCTX, NWBO, ERAS, and SANA Headlines

Recent News About These Companies

SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 29 at 10:00 PM | accessnewswire.com

Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky About Pending Class Action - SANA

April 29 at 4:30 PM | accessnewswire.com

Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline

April 29 at 1:10 PM | globenewswire.com

SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 29 at 9:45 AM | accessnewswire.com

SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 29 at 9:30 AM | prnewswire.com

Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

April 29 at 8:15 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA

April 29 at 8:00 AM | globenewswire.com

Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

April 29 at 7:30 AM | accessnewswire.com

SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

April 29 at 7:00 AM | accessnewswire.com

Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

April 29 at 5:45 AM | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA

April 28 at 8:30 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

April 28 at 8:05 PM | prnewswire.com

Sana Biotechnology, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA

April 28 at 6:30 PM | accessnewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA

April 28 at 6:21 PM | accessnewswire.com

Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky About Pending Class Action - SANA

April 28 at 2:45 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

April 28 at 2:15 PM | prnewswire.com

Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky About Pending Class Action - SANA

April 28 at 2:00 PM | accessnewswire.com

SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit

April 28 at 1:35 PM | prnewswire.com

Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact The Gross Law Firm about pending Class Action - SANA

April 28 at 12:31 PM | globenewswire.com

Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA

April 28 at 10:30 AM | accessnewswire.com

XTX Topco Ltd Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA)

April 27 at 4:03 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, NWBO, ERAS, and SANA Company Descriptions

Erasca NASDAQ:ERAS

$1.43 +0.03 (+2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 -0.01 (-1.05%)

As of 05:44 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.47 +0.01 (+2.39%)

Closing price 04:10 PM Eastern

Extended Trading

$0.47 0.00 (0.00%)

As of 07:50 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Northwest Biotherapeutics OTCMKTS:NWBO

$0.30 +0.02 (+5.37%)

As of 03:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Sana Biotechnology NASDAQ:SANA

$1.71 -0.05 (-2.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 -0.01 (-0.58%)

As of 07:57 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time